Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Arvaya Healthcare's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524723 vs MCK, COR, CAH: Buyback Yield % Comparison
For the Medical Distribution subindustry, Arvaya Healthcare's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arvaya Healthcare Buyback Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arvaya Healthcare's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Arvaya Healthcare's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arvaya Healthcare (BOM:524723) has a Buyback Yield % of -0.98 as of Aug. 13, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Arvaya Healthcare and its competitors. According to the industry distribution chart, Arvaya Healthcare ranks #24 out of 38 companies in the Medical Distribution industry, placing it in the top 63.2%.
Is Arvaya Healthcare's Buyback Yield % too high?
Arvaya Healthcare's current Buyback Yield % is -0.98. Based on the distribution chart, Arvaya Healthcare ranks #24 out of 38 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Arvaya Healthcare has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arvaya Healthcare's Buyback Yield % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Arvaya Healthcare ranks #24 out of 38 companies for Buyback Yield %. This places Arvaya Healthcare in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Distribution company?
A good Buyback Yield % depends on the Medical Distribution industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Arvaya Healthcare and its competitors. Arvaya Healthcare's current Buyback Yield % is -0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arvaya Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Arvaya Healthcare (BOM:524723) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹50.07, compared to a current price of ₹112.45 — trading 124.6% above its estimated fair value. The current Buyback Yield % is -0.98. Arvaya Healthcare's overall GF Score™ is 36/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Arvaya Healthcare (BOM:524723), the current Buyback Yield % is -0.98 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arvaya Healthcare (BOM:524723) Overvalued in 2026?
Based on GuruFocus' analysis, Arvaya Healthcare stock appears to be overvalued.
The current stock price of ₹112.45 is trading 124.6% above its estimated GF Value™ of ₹50.07.
GuruFocus considers Arvaya Healthcare to be Significantly Overvalued.
Key valuation signals for BOM:524723:
Buyback Yield %: -0.98
GF Value™: ₹50.07 vs. price of ₹112.45 (124.6% above fair value)
No single metric tells the full story. See the BOM:524723 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arvaya Healthcare Ltd is focused on developing an integrated healthcare platform in India that combines hospital services, diagnostics, wellness services, and digital health management solutions. Its operations include multi-specialty hospitals, a digital health platform for appointment booking and health record management, diagnostic services including laboratory testing and home sample collection, and wellness facilities offering preventive and recovery-focused programs.
36GF Score
Get the complete analysis for BOM:524723
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524723 has been successfully added to your 
